BBNX
Beta Bionics, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$16.75Close
$743.0MMarket cap
$8.86 – $31.9952-week range
Late-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 48% below its 52-week high
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
48%
1wk
down 12.6%
price change
1mo
down 11.7%
price change
12-month return
down 37%
market up 11% ·
its own down 48%
F-score
6 / 9
Mixed
Altman Z
9.71
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.6×
price / book
Earnings yield
down 10.1%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
up 54%
year on year
EPS growth
—
latest quarter
Sales growth
up 30%
latest quarter · -7 pts
ROE
down 25%
return on equity
Free cash margin
down 56%
-$56.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- issued more shares
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Trade setup
ATR%
8.7%
$1.46 a day · 2×ATR $13.83
RS
76 / 99
vs the universe
Trend
5 / 8
200-day not rising, under the 50-day, over 25% off the high
Relative volume
0.9×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
—
no scheduled report
Trend template · 5 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: passes
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 565.3% over the year, from 7m to 44m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 27, 2026
Last shock
Oct 28, 2026-17% in one session2.2× volumeon results-6% since
Financials
- Gross 55%
- Net -73%
- Free cash -56%
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Revenue | $12.0M | $65.1M | $100.3M |
| Gross margin | 53% | 55% | 55% |
| Operating income | -$35.9M | -$45.3M | -$71.7M |
| Net income | -$44.1M | -$54.8M | -$73.2M |
| Net margin | -368% | -84% | -73% |
| Earnings per share | -$8.31 | -$8.60 | -$1.81 |
| Free cash flow | -$32.8M | -$51.7M | -$56.2M |
| Free cash margin | -274% | -79% | -56% |
| Cash | $26.6M | $30.4M | $31.6M |
| Shareholders' equity | -$203.1M | -$245.4M | $287.6M |
| Shares outstanding | — | 6.67m | 44.36m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 27, 2026 | Quarterly ↗ | Sep 30, 2026 | 27d |
| Jul 29, 2026 | Quarterly ↗ | Jun 30, 2026 | 29d |
| Apr 21, 2026 | Quarterly ↗ | Mar 31, 2026 | 21d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Jul 29, 2025 | Quarterly ↗ | Jun 30, 2025 | 29d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Mar 25, 2025 | Annual ↗ | Dec 31, 2024 | 84d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Results ↗ |
| Sep 17, 2026 | Other events ↗ |
| Sep 15, 2026 | Regulation FD · Other events ↗ |
| Jul 29, 2026 | Results ↗ |
| May 22, 2026 | Shareholder vote ↗ |
| May 21, 2026 | Regulation FD · Other events ↗ |
| Apr 21, 2026 | Results ↗ |
| Feb 17, 2026 | Results ↗ |
| Jan 30, 2026 | Other events ↗ |
| Jan 8, 2026 | Results ↗ |
| Oct 28, 2025 | Results ↗ |
| Jul 29, 2025 | Results ↗ |